TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Electroacupuncture in Treating Chronic Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of primary head and neck cancer~* Has undergone radiotherapy either as primary or adjuvant therapy ≥ 6 months ago~  * One or more parotid glands must have been in the prior radiotherapy field~* Residual xerostomia after radiotherapy deemed to be significant by patient~  * Failed to respond to a trial of pilocarpine for relief of xerostomia~PATIENT CHARACTERISTICS:~* ECOG performance status 0-3~* Life expectancy ≥ 1 year (based on physician's judgment)~* Able to attend the scheduled study treatments~* Alert and mentally competent~* Not pregnant~* Willing to use contraception during study treatment, if of childbearing age~* No history of Sjögren's disease~* No cardiac pacemaker or any other electrical devices permanently implanted within the body (e.g., dorsal column stimulator)~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* More than 2 weeks since prior medication that may cause mouth dryness (e.g., antihistamines, narcotics, tricyclic antidepressants)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with peripheral arterial disease~* Participants must be 18 to 85 years of age~* Females must be postmenopausal or sterile~Exclusion Criteria:~* Participans with hepatic, HIV, endocrine, connective tissue, psychiatric disorders or uncontrolled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- MK-0736 (Type: EXPERIMENTAL): Participants will be orally administered 7 mg of MK-0736 once daily for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Participants will be orally administered placebo once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Pycnogenol on Cardiac Fibrosis and Diastolic Dysfunction in Aged Hypertensive Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The subjects will consist of ambulatory males and females, 50-75 years of age, of any race, diagnosed with hypertension (diagnosis made over 6 months), and echocardiographic evidence of grade I or II diastolic dysfunction.~* There is no need for standardization of hypertension treatment, as we select only patients who have diastolic dysfunction during treatment.~Exclusion Criteria:~* Unstable angina or myocardial infarction in the past 3 months.~* Biochemical evidence of renal or hepatic failure.~* Severe anemia: defined as hemoglobin level less than 7 g/dL.~* Current cancer or other major illness not associated with the heart.~* Bleeding disorders.~* Taking anticoagulants including low dose aspirin.~* Diabetes.~* Known allergy to Pycnogenol.~* Being pregnant or breastfeeding.~* Systolic blood pressure over 180 mmHg or less than 100 mmHg, and Diastolic blood pressure over 110 mmHg or less than 50 mmHg.~* Current smoking.~* Having breast implants.~* Taking any of the following: birth control products, Diethylstilbestrol, Ephedra, ephedrine, or pseudoephedrine (except where used in prescription products), hormone replacement products, Isotretinoin, any product containing mercury, Phentermine in combination with fenfluramine (including but not limited to Pondimin) or dexfenfluramine (Redux).

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Pycnogenol (Type: EXPERIMENTAL): 200 mg/day
- Control (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time-Of-Flight (TOF)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, aged more than 18 years~* Strongly suspected of having renal arterial disease~* Scheduled (or to be scheduled) to undergo arterial catheter-based X-ray angiography examination~Exclusion Criteria:~* Known grade IV or V chronic kidney disease (GFR\<30 mL/min/1.73m²)~* Contraindication to MRI~* Acute renal dysfunction within the 6 months preceding Dotarem®-enhanced MRA examination

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dotarem (Type: EXPERIMENTAL): Each subject will receive one injection of Dotarem 0.2ml/kg.
- Time Of Flight (Type: OTHER): Each subject will undergo a TOF Magnetic Resonance Angiography

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completion of study treatment (placebo or active) in the previous Phase 3, double-blind study protocol (Protocol PTC124-GD-021-CF)~* Evidence of signed and dated informed consent/assent document(s) indicating that the participant (and/or the participant's parent/legal guardian) has been informed of all pertinent aspects of the trial.~Exclusion Criteria:~* Known hypersensitivity to any of the ingredients or excipients of the study drug.~* Ongoing participation in any other therapeutic clinical trial.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ataluren (Type: EXPERIMENTAL): Participants will be administered ataluren orally at a dose of 10 milligrams/grams (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for up to 96 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically documented non-small cell lung cancer, Stages 3B, 4 or recurrent~* Pleural effusion cytologically proven to be malignant~* 0 or 1 prior chemotherapy regimens for non-small cell lung cancer (adjuvant chemotherapy post resection, or concurrent chemo-radiation therapy counts as one regimen regardless of number of agents used.)~* Planning to start chemotherapy for non-small cell lung cancer (treatment regimen at discretion of treating physician but must include one or more of the following agents:cisplatin,carboplatin,docetaxel,paclitaxel, pemetrexed,gemcitabine,vinorelbine) Patients may receive anti-angiogenesis agents (bevacizumab) in addition to chemotherapy, but patients treated solely with tyrosine kinase inhibitors or growth-factor receptor blockers are not eligible.~* Prior radiation therapy is permitted.~* Performance status 0,1,2~* Serum creatinine less than 2.0 or estimated creatinine clearance over 30cc/min by Calcroft/Gault equation~* Estimated life expectancy over 3 months~* Signed informed consent~* Age greater than 18 years~* Patients who have clinical indication for Zometa treatment such as lytic bone metastases or hypercalcemia can be included~Exclusion Criteria:~* Pregnant or lactating~* Patient with concurrent medical or psychiatric illness which would, in the opinion of the investigator, prevent compliance with the study~* Patients who undergo any procedure other than thoracentesis for drainage of effusion.Patients may have had more than one thoracentesis prior to study. Patients who have large bore chest tube placement, permanent transthoracic catheter (Pleurex), medical pleurodesis or thoracoscopy are excluded.~* Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular);dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures.~* Recent (within 6 weeks)or planned dental or jaw surgery (e.g.extraction, implants).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zoledronic Acid (Type: EXPERIMENTAL): Zometa administered as a 15 minute IV infusion of either 4 mg, 3.5mg, 3.3 mg or 3.0 mg every 4 weeks based on the patient's baseline calculated creatinine clearance(CrCl)using the Cockcroft-Gault formula.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Do Taxes Reduce the Purchasing of Soda?

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* All patrons who purchase a beverage at our study site (retail cafe) during the intervention are eligible for inclusion. The cafe is open to the public, though it primarily serves staff, patients and guests of the research labs in the building.~Exclusion Criteria:~* There are no exclusion criteria.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Business as Usual (No Tax) (Type: NO_INTERVENTION): Baseline data where business 'as usual' will be conducted and no price increases will be implemented on SSBs.
- General Tax (without named beneficiary) (Type: EXPERIMENTAL): In the general tax condition investigators will introduce a 3 cent/ounce tax on the five SSB flavors the café offers. An example of this sign would be 'Pepsi, $2.29, includes 60 cent sugary drink surcharge.'
- Pre-K Tax (Type: EXPERIMENTAL): In the Pre-K tax condition investigators will institute a 3 cent/ounce tax but will label the tax as proceeds going to Pre-K education. An example of this sign is, Pepsi, $2.29, includes a 60 cent sugary drink surcharge to fund Pre-K education.
- Childhood Healthy Eating Tax (Type: EXPERIMENTAL): In the Childhood Healthy Eating tax condition investigators will institute a 3 cent/ounce tax but will label the tax as proceeds going to Pre-K education. An example of this sign is, Pepsi, $2.29, includes a 60 cent sugary drink surcharge to fund Childhood Healthy Eating education.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Tourniquet Pressure in Primary Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 - 80 years old~2. primary TKA, not revision~Exclusion Criteria:~1. systolic blood pressure (BP) ≥ 170 mmHg~2. one-staged bilateral TKA or stages less than three months apart~3. history of peripheral vascular disease~4. history of thromboembolism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- 220 mmHg tourniquet cuff pressure (Type: ACTIVE_COMPARATOR): Thigh tourniquet cuff inflated to 220 mmHg.
- 250 mmHg tourniquet cuff pressure (Type: ACTIVE_COMPARATOR): Thigh tourniquet cuff inflated to 250 mmHg
- 275 mmHg tourniquet cuff pressure (Type: ACTIVE_COMPARATOR): Thigh tourniquet cuff inflated to 275 mmHg
- 300 mmHg tourniquet cuff pressure (Type: ACTIVE_COMPARATOR): Thigh tourniquet cuff inflated to 300 mmHg
- 325 mmHg tourniquet cuff pressure (Type: ACTIVE_COMPARATOR): Thigh tourniquet cuff inflated to 325 mmHg
- 350 mmHg tourniquet cuff pressure (Type: ACTIVE_COMPARATOR): Thigh tourniquet cuff inflated to 350 mmHg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Concussion in Rugby Players: a Pilot Study of Neural Recovery Using fMRI

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* no neurological or psychiatric disease~* recent history of concussion (\<3 months) according to the Rugby French Federation criteria.~Exclusion Criteria:~* Inability to be assessed by MRI

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Concussion Group (Type: EXPERIMENTAL): Players with a recent (\<72 hours) history of concussion will be assessed 3 times. just after concussion, after disappearance of clinical symptoms and 3 months after the previous visit. During each visit, participant will undergo a neurological and a neuropsychological assessment and a structural and resting state fMRI.
- Control Group (Type: ACTIVE_COMPARATOR): a control group with no history of concussion will be the comparator. Participants will be assessed 3 times. Visits will be the same for the control group and duration between visits in this group will be matched to the concussion group. During each visit, participant will undergo a neurological and a neuropsychological assessment and a structural and resting state fMRI.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Preliminary Study Utilizing a Flexible Endoscope for Pelvic Culdoscopy

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female~* Ages 18 to 70 years old~* Ability to understand and give informed consent~* Scheduled for diagnostic or therapeutic laparoscopy for a clinical indication~* Presence of a uterus and at least one ovary at the initiation of the procedure~Exclusion Criteria:~* Documented culdesac mass~* Inability to tolerate anesthesia~* Documentation of positive urine pregnancy test~* History of prior pelvic radiation~* Scheduled for emergency laparoscopy~* Any other medical or psychiatric condition that, in the opinion of the investigative team, will interfere with the ability of the participant to safely complete the study~* History of significant non-compliance with previous therapy or unwillingness to return for follow up visits~* Prior hysterectomy and/or bilateral salpingo-oophorectomy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 - Device (Type: None): The principal Investigator and sub-investigators of this study will identify potential participants that attend the gynecologic oncology or gynecology clinics of UAMS. These subjects will have been scheduled for diagnostic or therapeutic laparoscopy. Based on the Inclusion Criteria and Exclusion Criteria of this study, women who are eligible for the study will be approached to participate.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Additional Platelet Inhibition in Patients With High Platelet Reactivity Undergoing Percutaneous Coronary Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ACS patients with intent for PCI \<72 hours from admission.~2. Prior clopidogrel loading within 24h before planned PCI or chronic (\>24 hours) treatment with clopidogrel~3. High platelet reactivity (HPR) PA \> 400 AU min by multiplate analyser (poor responders)~4. Initial platelet function sample at least 2 hours after pre PCI loading dose~5. Consent~Exclusion Criteria:~1. Patients \<18 years and \>75 years~2. Body weight \<60kg~3. Pretreatment with prasugrel within 7 days of randomisation~4. History of stroke or transient ischaemic attack~5. Patients with increased bleeding risk e.g.~   * recent major trauma or surgery~  * gastrointestinal bleeding or active peptic ulceration~  * Platelet count \<100,000 / mm3 at the time of screening~  * Internationally Normalized Ratio (INR)\> 1.5 at the time of screening~6. Hb\<10g/dL~7. Intracranial neoplasm, arteriovenous malformation or aneurysm.~8. Severe hepatic impairment (Child Pugh class C)~9. Intention to use the following medications~   * oral anticoagulation~  * other antiplatelet therapy (including GPIIb/IIIa inhibitors) besides aspirin~  * nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors~10. Female patients who are pregnant, planning pregnancy, not using reliable contraception or who are breastfeeding~11. Known allergy, hypersensitivity or other contraindications to prasugrel or clopidogrel

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Prasugrel (Type: ACTIVE_COMPARATOR): Day 1 loading 60mg Day 2 to 7 10mg o.d. Day 8 to 30 days 10mg od
- Clopidogrel (Type: ACTIVE_COMPARATOR): Day 1 Loading 600mg Day 2 to 7 day: 150mg o.d. Day 8 to 30 days: 75mg o.d.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Anti-tumor Immune Response in Patients With Cancer Undergoing Radiation Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated Institutional Review Board (IRB)-approved Informed Consent form for the study~* Received an explanation of the study, including satisfactory answers to all questions related to the proposed research~* Is undergoing physician directed radiation treatment~Exclusion Criteria:~* The potential Subject is unwilling or hesitant to participate for any reason and/or fails to complete the appropriate Informed Consent form

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ancillary-Correlative (blood banking) (Type: None): Samples of blood are collected before, during, and within two weeks after radiation therapy and then stored for analysis of anti-tumor immunity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Erector Spinae Block for Spine Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Adults aged greater than or equal to 18 years old and less than or equal to 85 years old.~* Patients who are scheduled to undergo lumbar spinal surgery (1-2 level) and willing and able to provide informed consent.~Exclusion criteria:~* Patients with a history of chronic opioid use for \> 3 months including but not limited to fentanyl, morphine, oxycodone, methadone.~* Patients with known allergy or intolerance to any drug used in the study including local anesthetics and total intravenous anesthesia medications.~* Patients with a history of alcohol or drug abuse.~* Patients with a history of intolerance of nonsteroidal anti-inflammatory drugs.-Patients with hepatic insufficiency.~* Patients with renal insufficiency.~* Patients who are pregnant.~* Patients with American Society of Anesthesiologists physical status of 4 or greater.~* Patients on immunosuppressive therapy. Pregnant patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Bupivacaine only (Type: ACTIVE_COMPARATOR): bupivacaine 0.25% in ESP blocks
- Liposomal Bupivacaine and Bupivacaine (Type: EXPERIMENTAL): liposomal bupivacaine in addition to 0.25% bupivacaine in ESP blocks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues